Safety of EGCG for treatment of grade III RID
skin ulcer
ADVERSE EVENTS, SKIN ULCER
The dose of EGCG solution began from 660 to 2574 μmol/L, no adverse events were observed and reported associated with EGCG. And also, no EGCG dose reduction because of adverse events of skin. Even for the skin ulcer after RT, EGCG was well tolerated for all patients. Thus, the highest dose of this Phase I trial (2574 μmol/L) was recommended for continuous Phase II trial for further evaluation.